A new study reveals that glucagon-like peptide-1 receptor agonists (GLP-1), which include weight loss and diabetes meds ...

New research shows that Ozempic and similar drugs reduce opioid overdoses by 40% and alcohol intoxication by 50% in people ...

Ozempic and other semaglutide medications for weight loss have been linked to hair loss on social media. Experts share who is ...

Facial volume loss and increased skin laxity were significant in the mid-cheek region after major weight loss, resulting in accelerated facial aging.

Only 15% of those who start a glucagon-like peptide 1 (GLP-1) for weight loss are still taking it two years according to ...

The use of GLP-1 RAs is associated with the risk for retained gastric contents and inadequate bowel preparation during endoscopic procedures.

The FDA has already made more than a dozen cancer drug approval decisions this year and more expected in the next several ...

As previously reported in Women’s Health, semaglutide injections mimic the effects of a hormone called glucagon-like ...

Patients aged 10 to 17 years who are prescribed glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are more likely to have comorbid type 2 diabetes, high body mass index, and a previous metformin ...

Newer weight loss drugs are cost effective in the long term only when combined with bariatric weight loss surgery, according ...

A large study of veterans with type 2 diabetes finds better short-term kidney outcomes with use of SGLT2 inhibitors vs GLP-1 receptor agonists.

GLP-1 receptor agonists and similar drugs may protect people with opioid or alcohol use disorder from opioid overdose and ...